Pharmacological effects and clinical evaluation of zilucoplan for generalized myasthenia gravis
Zilucoplan is a novel subcutaneous self-administered macrocyclic peptide inhibitor of complement component 5.It was approved by the FDA in October 2023 for the treatment of adults with generalized myasthenia gravis(gMG)who are positive for acetylcholine receptor(AChR)antibodies.This article reviews its pharmacological action,pharmacokinetics,clinical evaluation and safety.
zilucoplaninhibitor of complement component 5generalized myasthenia gravisclinical evaluationsafety
国家科技期刊平台
NSTL
万方数据
